top of page

Letter to the Shareholders from President Raivo Unt

Rafarma Pharmaceuticals, Inc. (OTC: RAFA) shares the following letter to shareholders from President Raivo Unt.

It is my pleasure to address some questions surrounding the current company status and clarify steps that we made recently to ensure shareholder value and maximum transparency.

Rafarma Pharmaceuticals was unfortunately affected by geo-political issues in Eastern Europe, and we have made a lot to protect the company during the past year. I have been appointed to assist with the company management associated with Rafarma Pharmaceuticals.

I began my career in the pharmaceutical industry in 1999 as Finance Director of JSC Tallinn Pharmaceutical Plant, where I managed the company assets, financial resources and cash. Seven years later, I became the CEO. A significant career part I devoted to JSC Kevelt. I have also participated in new pharmaceutical production sites varying in complexity and size. I have participated in the launching of Oriola (Finland), Olainfarm (Latvia), Grindex (Latvia), TFT (Estonia), Interchemie Werken De Adelaar AS (Estonia), Probiiomed (Mexico).

The current issue has required the removal of Kraspharma as a consolidated company. However, we intend to keep Kraspharma's financials transparent to the shareholders and consolidate the company as soon as it will be possible. The companies currently being audited are associated with Biocogency and its affiliate companies. We will provide the audit as soon as it will be completed. I will have further communication regarding timelines in the coming weeks.

My experience in the pharmaceutical industry gives me a strong feeling that Rafarma Pharmaceuticals is in a unique situation. With proper management, it will become an extremely profitable company with a global humanitarian goal - to help people worldwide. I am happy to be part of Rafarma Pharmaceuticals.


Rafarma Pharmaceuticals is a diversified pharmaceutical company dedicated to the new treatments and solutions development for patients in various fields. Regularly cooperating with leading research institutes and pharmaceutical companies around the world, the business has earned a reputation as a reliable manufacturer and distributor. Rafarma Pharmaceuticals has more than 25 programs in molecular biology, nuclear medicine, immunology, sustainable packaging and many other fields at the moment.

For more information, please visit



(307) 429-2029

Source: Rafarma Pharmaceuticals, Inc.


bottom of page